SOL-GEL TECHNOLOGIES LTD
Develops innovative dermatological treatments for skin conditions.
Stock Performance Snapshot
Analyst Rating
Analysts recommend selling SOL-GEL Technologies' stock with a target price of $6, indicating significant downside.
Financial Health
Sol-Gel Technologies is generating modest revenue and cash flow, with a stable book value per share.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Baskets Featuring SLGL
Injectable Drug Innovation Opportunities 2025
The FDA's approval of an at-home injectable version of Eisai and Biogen's Alzheimer's drug, Leqembi, simplifies treatment for patients and caregivers. This development highlights a growing trend toward patient-centric care, creating investment opportunities in companies that specialize in innovative drug delivery systems and at-home therapeutic technologies.
Published: August 31, 2025
Explore BasketOral Obesity Treatments: Beyond The Needle
Following successful Phase 3 trials for its oral weight-loss drug, orforglipron, Eli Lilly is positioned to enter the lucrative obesity treatment market. This development creates a new investment theme focused on pharmaceutical companies developing patient-friendly, oral alternatives to injectable GLP-1 therapies.
Published: August 27, 2025
Explore BasketWhy You’ll Want to Watch This Stock
Commercial traction watch
Monitor contract wins and customer pilots as signs of commercial adoption; remember small‑cap announcements can move the share price significantly and outcomes vary.
Technology edge
Proprietary sol‑gel processes can offer differentiation in coatings and functional surfaces, but continued R&D and scale‑up are needed to turn innovation into reliable revenue.
End‑market exposure
Performance depends on demand in industries like industrial manufacturing and specialty applications; macro cycles and supply chains can influence results.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals develops treatments for diseases including cystic fibrosis and cancer.
Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals is a leading biotechnology company that develops and manufactures innovative medicines for serious medical conditions.
Alnylam Pharmaceuticals, Inc.
Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company focused on discovering, developing and commercializing therapeutics based on RNA interference (RNAi).
